{"url_path":"/sec/bbio/8-k/2026-06-26/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-026506-index.html","accession_number":"0001140361-26-026506","cik":"0001743881","ticker":"BBIO","issuer_name":"BridgeBio Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-026506-index.html","primary_entity_key":"0001743881","primary_entity_name":"BridgeBio Pharma, Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit\n\nNo.\n\nDescription\n\n[10.1](ef20076710_ex10-1.htm)\n\nBridgeBio Pharma, Inc. Third Amended and Restated 2021 Stock Option and Incentive Plan and form award agreements thereunder\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\nBRIDGEBIO PHARMA, INC.\n\nDate: June 26, 2026\n\nBy:\n\n/s/ Thomas Trimarchi\n\nName:\n\nThomas Trimarchi, Ph.D.\n\nTitle:\n\nPresident and Chief Financial Officer"}